Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Agios Pharmaceuticals’ dense clinical disclosures can feel like hunting for a single mutation in a genome. R&D expenses tied to pyruvate-kinase activators, FDA feedback on sickle-cell trials, and collaboration milestone payments sprawl across hundreds of pages. If you have ever asked, “How do I read the Agios Pharmaceuticals annual report 10-K simplified?” or searched for “Agios Pharmaceuticals insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI-powered analysis turns that challenge into clarity. Our system ingests every 10-K, 10-Q, 8-K and S-1 the moment it hits EDGAR, then delivers plain-English summaries that highlight trial progress, cash runway and key risks—Agios Pharmaceuticals SEC filings explained simply. You can monitor Agios Pharmaceuticals Form 4 insider transactions real-time, receive alerts on Agios Pharmaceuticals quarterly earnings report 10-Q filing numbers, and access AI commentary that points to pivotal PK-activation data. Whether you need an Agios Pharmaceuticals earnings report filing analysis or a quick read on an Agios Pharmaceuticals 8-K material events explained, the insights are waiting.
Investors use this page to:
- Track Agios Pharmaceuticals executive stock transactions Form 4 before catalytic trial read-outs
- Compare period-over-period R&D spend without sifting through footnotes
- Review the Agios Pharmaceuticals proxy statement executive compensation for alignment with shareholder interests
- Gauge cash runway against pipeline timelines in seconds—understanding Agios Pharmaceuticals SEC documents with AI
Insider sale notice under Rule 144: This Form 144 records a proposed sale of 200 common shares by an insider through Morgan Stanley Smith Barney LLC on
The filer also reported three prior sales by the same person in the past three months: 200 shares on
David Scadden, a director of Agios Pharmaceuticals (AGIO), reported trading activity executed on 09/30/2025 under a Rule 10b5-1 trading plan. The filing shows a purchase of 200 common shares at $18.09 and a sale of 200 common shares at $40.00 on the same date. After those transactions Mr. Scadden reported beneficial ownership of 17,603 shares of common stock and, including derivative holdings, 27,307 shares underlying options.
The Form 4 also reports an option grant with an exercise price of $18.09 and an expiration date of 06/21/2032. The filer notes the option grant was originally made on 06/21/2022 and that the underlying shares vest 100% one year from the grant date. The filing is signed by an attorney-in-fact on 10/02/2025.
Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals (AGIO) reported the vesting of 7,472 restricted stock units and a contemporaneous automatic sale of 3,651 shares to satisfy tax withholding obligations. The sale price reported was $36.77 per share, and following these transactions she beneficially owned 33,870 shares. The RSUs were originally granted on September 26, 2022 and vest in three equal annual installments beginning September 26, 2023. The tax-withholding sale was executed under pre-existing durable automatic sale instructions consistent with a Rule 10b5-1 plan.
Form 144 filed for Agios Pharmaceuticals (AGIO) reporting proposed sale of common shares by an insider. The notice identifies David T. Scadden as the person for whose account the securities will be sold. The filing shows 200 shares intended for sale through Morgan Stanley Smith Barney LLC on 09/30/2025 with an aggregate market value of $8,000. The shares were acquired by a stock option exercise on 09/30/2025 and paid for in cash. The filing also discloses two prior sales by the reporting person within the past three months: 200 shares on 08/27/2025 for $8,000 and 1,400 shares on 07/10/2025 for $56,000. The notice includes the required representation that the seller does not possess undisclosed material adverse information.
Form 144 notice for AGIO (Agios Pharmaceuticals, Inc.) reporting a proposed sale of 3,651 shares of common stock via Morgan Stanley Smith Barney. The filing states the aggregate market value of the shares is $134,247.00 and lists 58,101,518 shares outstanding. The securities were acquired through the vesting of restricted stock units on 09/26/2025 and the same date is shown as the approximate sale date and payment date. The filer reports no securities sold in the past three months.
Theodore James Jr., identified as a Principal Accounting Officer of Agios Pharmaceuticals (AGIO), reported a sale of 8,546 shares of the issuer's common stock on 09/05/2025 at a reported price of $36.87 per share. After the reported transaction, the filing shows 868 shares beneficially owned by the reporting person in a direct form. The disclosure is a standard Section 16 Form 4 reporting an insider sale.
David Scadden, a director of Agios Pharmaceuticals, reported transactions dated 08/27/2025 under a Rule 10b5-1 plan. He exercised an option to acquire 200 shares of common stock at an exercise price of $18.09 and sold 200 shares at $40.00. The Form shows beneficial ownership of common stock of 17,803 shares following the acquisition and 17,603 shares following the sale. The related option was originally granted on June 21, 2022 and vested 100% one year after grant. The filing is signed by William Cook as attorney-in-fact on 08/29/2025.
Paradigm BioCapital and related entities reported beneficial ownership of 3,027,977 shares of Agios Pharmaceuticals common stock, representing 5.2% of the outstanding class. The filing shows the position as of the close of business on August 21, 2025 and explains that the total includes 2,827,977 shares directly held (2,493,645 by Paradigm BioCapital International Fund Ltd. and 334,332 by a separately managed account) plus 200,000 shares underlying call options exercisable within 60 days (176,300 attributable to the Fund and 23,700 to the Account). The reporting group bases percentages on 58,101,518 shares outstanding as of July 25, 2025. The filing states these holdings are not intended to influence control of the issuer and includes a joint filing agreement.
Agios Pharmaceuticals (AGIO) Form 144 notice: The filing reports a proposed sale of 200 common shares through Morgan Stanley Smith Barney on 08/27/2025 with an aggregate market value of $8,000. The shares were acquired the same day by stock option exercise and paid in cash.
The filing also discloses a prior sale by David Scadden of 1,400 common shares on 07/10/2025 for gross proceeds of $56,000. The issuer's outstanding shares are listed as 58,101,518, and the proposed sale is to be executed on the NASDAQ.
Rahul Ballal, a director of Agios Pharmaceuticals (AGIO), reported a transaction dated 08/11/2025 involving restricted stock units and common stock. The filing records a grant of 2,302 restricted stock units, each representing a contingent right to receive one share, originally granted on 08/11/2022; the underlying shares vest in three equal annual installments beginning 08/11/2023. The report shows a price of $0 for the restricted units.
Following the reported transaction the filing shows Mr. Ballal beneficially owns 12,414 shares of Agios common stock in a direct capacity.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
